flow trial semaglutide nejm π¨#FLOW: The most anticipated of the year now published in @NEJM with #ERA24 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself Frontiers | Cardiovascular Safety and
Description
I think these drugs that affect multiple final common pathways are really highly effective because when we try to just treat one risk factor, its almost like putting your finger in the dike

PeerJ 9, e11128
Thigh The front of your thigh also has a decent fat layer, which makes it another good option for subcutaneous injections
The consistency should be similar to water

Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, studied for its powerful weight reduction and metabolic improvement potential Not a member
